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KEY POINTS
 Pulmonary hypertension can be frquently associated with HFpEF and is associated with worsened
symptoms and mortality.
 Although right heart catheterization is the gold standard for diagnosing pulmonary hypertension,
the echocardiogram raimains the screening test of choice and provides insightful information about
hemodynamics.
 Currently, therer are no pulmonary hypertension sppecific medications approaved for PH-HFpEF
and treatment remains focused to optimizing co-morbidities.

Heart failure with preserved ejection fraction
(HFpEF) is a common entity that predominately affects older adults. Epidemiologic trends show that
the incidence of HFpEF has not declined as profoundly as heart failure with reduced ejection fraction (HFrEF), and overall mortality remains
unchanged.1 Pulmonary hypertension (PH) is a
heterogeneous condition defined hemodynamically as an elevation of pulmonary artery (PA) pressures and is commonly associated with HFpEF.
Clinically, PH can be classified into 5 distinct categories based on the etiology, underlying pathophysiology, and potential treatment options.2 Of
these categories, PH due to left heart disease
(PH-LHD) is frequently seen in clinical practice
and is most commonly a consequence of the underlying left heart condition and probably related
to its severity and duration.3,4 The association of
PH and HFpEF (PH-HFpEF) can be found in a majority of patients with HFpEF and is associated with
worse symptoms and increased mortality.5

Despite the advancements in the treatment of
other forms of PH, such as pulmonary arterial hypertension (PAH), pulmonary hypertension due to
interstitial lung disease (PH-ILD) and chronic
thromboembolic
pulmonary
hypertension
(CTEPH), effective treatment of PH-LHD has not
been found yet.6–9

HOW SHOULD PULMONARY HYPERTENSIONHEART FAILURE WITH PRESERVED EJECTION
FRACTION BE DEFINED?
PH was traditionally defined as a mean PA pressure  25 mm Hg based on a resting right heart
catheterization (RHC). This threshold has been
considered arbitrary and inconsistent with recent
hemodynamic data of healthy individuals showing
an average mean PA pressure of 14  3.3 mm Hg,
a value that was minimally influenced by age. This
had led to a recent change in the cutoff for
elevated pulmonary pressures as a mean PA pressure > 20 mm Hg during the most recent World
Symposium in Pulmonary Hypertension.10 Despite
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the recognition of this lower diagnostic threshold,
PH-LHD continues to be defined as a mean PA
 25 mm Hg and a pulmonary capillary wedge
pressure (PCWP) > 15 mm Hg.7 The definition of
PH-LHD relies heavily on the accurate measurement of PCWP and special attention should be
placed on measurements at end of expiration. In
sinus rhythm, this corresponds to the mean of
the A-wave.7
PH-LHD can be a result of several factors,
including the passive transmission of elevated
left-sided filling pressures, pulmonary vasculopathy, increased pulmonary blood flow, or a combination of these elements. Understanding the
underlying pathophysiology may help in guiding
medical management and selecting future therapeutic options. PH-LHD can be further divided
into 2 categories based on PCWP and pulmonary
vascular resistance (PVR): (1) isolated postcapillary pulmonary hypertension (IpcPH) when
PCWP > 15 mm Hg and PVR < 3 WU; and (2) combined pre and postcapillary pulmonary hypertension (CpcPH) when PCWP > 15 and PVR  3
Wood units. Although previously the diastolic
pressure gradient (DPG 5 PA diastolic–PCWP)
was introduced to distinguish between IpcPH
and CpcPH, this definition was found restrictive
and exposed to interpretation, leading to PVR being subsequently reintroduced as part of the definition.7 The importance of differentiating CpcPH
from IpcPH is highlighted by a meta-analysis of
10 retrospective analyses showing that PVR was
a strong predictor of survival.11 Similarly, a recent
large retrospective analysis also showed that PVR
was a predictor of mortality and hospitalizations in
HFpEF.12
As routine invasive RHC is often not performed
as part of the diagnosis of HFpEF, the initial
assessment of PH may rely heavily on an echocardiogram. Many studies which studied PH-HFpEF
did so by using the echocardiogram to define
PH. The probability of PH can be estimated based
on the peak tricuspid regurgitation velocity and the
presence of other supporting PH signs -RV/LV ratio >1.0, flattening of interventricular septum, right
ventricular outflow tract notching or short acceleration time, elevated right atrial pressures based on
IVC measurements- (Table 1), although most of
these signs reflect an elevated PVR which not
may necessarily be abnormal in PH-HFpEF.13

IS PULMONARY HYPERTENSION-HEART
FAILURE WITH PRESERVED EJECTION
FRACTION COMMON?
Lam and colleagues5 reported an incidence of the
PH of 83% based on echocardiographic data with

a median right ventricular systolic pressure (RVSP)
of 48 mm Hg in patients with HFpEF in Olmsted
County. Also, the TOPCAT study showed that
36% of patients with had estimated systolic PA
pressure of at least 35 mm Hg plus right trial pressure measured by echocardiogram.14
Strange and colleagues3 performed a large
observational population cohort study in Australia
which showed that 9.1% of echocardiograms performed showed evidence of PH (estimated
RVSP > 40 mm Hg). Based on clinical and echocardiographic data, patients were classified into
in one of the 5 distinctive groups based on the
updated classification at the time from the Third
World Symposium on Pulmonary Hypertension.15
PH-LHD was the most common type of PH diagnosed accounting for 68% of cases and an estimated incidence of 250 cases per 100,000. The
presence of PH was significantly associated with
poor survival. The mean survival rate for patients
with PH-LHD was 4.3  0.3 years. Interestingly,
the survival for patients with PAH was better than
those with PH-LHD, presumably because medical
therapy was available.

WHAT ARE THE CLINICAL IMPLICATIONS OF
PULMONARY HYPERTENSION IN HEART
FAILURE WITH PRESERVED EJECTION
FRACTION?
The deleterious association of PH-LHD and survival were also assessed by Lam and colleagues5
who used a random sample of patients with available echocardiographic data from Olmsted
County, Minnesota. The increase in RVSP was
coupled with increases in pulse pressure and
echocardiography-derived PCWP, suggesting
that age-associated blood vessel stiffness and
diastolic dysfunction contribute to changes in pulmonary artery pressure. After adjusting for estimated PCWP, RVSP was higher in HFpEF
compared to hypertensive individuals without
heart failure. This suggests that beyond the postcapillary contribution of pulmonary venous
congestion, a precapillary component may
contribute to greater PH in HFpEF. The presence
of PH defined by an RVSP above 35 mm Hg was
strongly associated with mortality. Moreover, mortality was higher in those with an RVSP above the
median of 48 mm Hg.
The presence of PH-HFpEF and RV dysfunction
is associated with increased mortality.16,17
Mohammed and colleagues18 demonstrated in a
community-based study that any degree of RV
dysfunction was found in about 21–35% of patients -semi qualitatively or tricuspid annular plane
systolic excursion (TAPSE) derived, respectively,
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Table 1
Echocardiography probability of PH

Peak TR Velocity (m/sec)

Other Echocardiogram
Findings Suggestive of PH

Echocardiographic Probability of PH

 2.8 or unable to measure
 2.8 or unable to measure
2.9–3.4
2.9–3.4
>3.4

Absent
Present
Absent
Present
Not required

Low
Intermediate
Intermediate
High
High

Supporting echocardiographic findings of PH: right ventricular to left ventricular basal diameter ratio> 1, flattening of
the interventricular septum (eccentricity index > 1.1 in systole and/or diastole), right ventricular outflow tract Doppler acceleration time < 105 msec and/or midsystolic notching, early pulmonary regurgitation velocity > 2,2 m/sec, pulmonary
artery diameter > 25 mm, inferior vena cava diameter > 21 mm with decreased respiratory variation (<50% with sniff
or < 20% quiet inspiration, right atrial area at end of systole > 18 cm2.

with HFpEF. Both RV dysfunction and elevated
RVSP were associated with worse cardiovascular
mortality and more frequent heart failure hospitalizations. Melenovsky and colleagues19 described
that 33% of patients with HFpEF had RV dysfunction -as defined by fractional area change < 35%in a single-center study of patients who underwent RHC. Those with RV dysfunction had higher
right heart filling pressures and more severe pulmonary vascular disease (higher PA pressures
and PVR). Patients with HFpEF with RV dysfunction had higher mortality when compared to patients without RV dysfunction (median 2-year
survival 56% vs 93%), and RV dysfunction was
the strongest predictor for mortality (HR 2.4 CI
1.6–2.6).

HOW CAN PULMONARY ARTERIAL
HYPERTENSION AND PULMONARY
HYPERTENSION-HEART FAILURE WITH
PRESERVED EJECTION FRACTION BE
DIFFERENTIATED?
PH is usually suspected after an echocardiogram
is performed in the setting of dyspnea on exertion
and shows an elevated estimated RVSP. Although
RHC is the definitive test of choice to define PH,
echocardiography remains the screening test of
preference for the initial evaluation and management of this condition. When findings such as
decreased left ventricular systolic function or severe aortic or mitral valve pathology are present,
the diagnosis of PH-LHD may be evident. On the
other side, an elevated RVSP in the setting of preserved left ventricular ejection fraction may represent a diagnostic dilemma between PAH and PHHFpEF. The echocardiogram is essential in generating an initial suspicion of the cause of PH and to
predict hemodynamics (Table 2).20

The accuracy of echocardiography to diagnose
PH was assessed in the Registry to Evaluate Early
and Long-term PAH Disease Management
(REVEAL), a large United States-based PH registry.21 In patients who had both an echocardiogram and RHC performed on the same day,
echocardiography underestimated RVSP in 29%
of the cases, it overestimated RVSP in 31% of
the cases and RVSP was within 10 mm Hg of
RHC in 40% of the cases. This correlation did
not change significantly whether the tests
occurred on the same day or within 12 months.
This study highlights the importance of invasive
hemodynamic assessment when suspecting significant PH.
An assessment of the morphology of the RV can
help predict hemodynamics and the cause of
PH.22 Raza and colleagues showed that an endsystolic RV base/apex ratio < 1.5 strongly correlates with an elevated PVR. In contrast, the RV
base was twofold wider—end-systolic RV base/
apex ratio > 2—than the apex in patients with
PH-LHC. Of note, patients with CpcPH showed a
low end-systolic RV base/apex ratio < 1.5, resembling those with PH due to pulmonary vascular disease. These findings are likely explained by the
impact elevated RV afterload on the RV compared
to elevated pressures due to passive left-sided
pressure transmission.
Arkles and colleagues23 demonstrated that a
simple visual inspection of the right ventricular
outflow tract (RVOT) Doppler provides a powerful
insight into the hemodynamics in a diverse PH
cohort. The presence of a midsystolic notch in
the RVOT Doppler was highly sensitive and specific for the triad of markedly elevated PVR,
decreased pulmonary vascular compliance, and
RV dysfunction seen in patients with PH due
to pulmonary vascular disease. On the other
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Table 2
Echocardiographic findings that help differentiate precapillary PH vs postcapillary PH in patients with
normal left ventricular systolic function
Precapillary PH (PAH)

Echocardiogram Parameter

Postcapillary PH (PH-HFpEF)

Usually normal or small
Bows right to left
< 1.5

Left atrial size
Interatrial septum
Right ventricle morphology
(end-systolic RV base/apex
ratio)
RVOT Doppler midsystolic
notch and/or short RVOT
acceleration time < 80 ms.
Prediction rule:
LA diameter: < 3.2 cm 5 11
LA diameter: > 4.2 cm 5 1
RVOT notching and/or AT <
80 ms 5 11
Lateral mitral E/e’: > 10 5 1
Mitral E/A ratio

Usually dilated
Bows left to right
>2

Present

Higher score

<1

Absent

Lower score

>1

Abbreviations: LA, left atrium; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PH-HFpEF: pulmonary
hypertension due to heart failure with preserved ejection fraction; RV, right ventricle; RVOT, right ventricular outflow
tract.

hand, PH in the absence of RVOT notching typically occurred in the setting of left heart
congestion.
A simple prediction rule including left atrial
diameter (11 point for diameter < 3.2 cm and 1
point for diameter > 4.2 cm), RVOT Doppler notching assessment (11 if present) or RVOT acceleration time (11 if < 80 msec) and lateral mitral E/e’
( 1 if > 10) accurately defines PH hemodynamics.24 In this study of patients with normal
left ventricular ejection fraction referred for the
evaluation of PH, PVR increased stepwise with
higher scores (score range 2 to 12). Negative
scores argue strongly against PH due to a pulmonary vasculopathy. In addition, a negative score in
conjunction with normal RVOT acceleration time
and preserved RV function essentially excluded
elevated PVR.

ARE THERE TREATMENT OPTIONS FOR
PATIENTS WITH PULMONARY
HYPERTENSION-HEART FAILURE WITH
PRESERVED EJECTION FRACTION?
While pulmonary vasodilators are the standard of
care in the treatment of PAH, results have not
been consistently replicated in patients with PHLHD; although these medications are sometimes
tried in a patient with PH-HFpEF because of the significant symptoms and poor prognosis that is associated with this patient population. There have been
trials using phosphodiesterase 5 inhibitors (PD5i),

soluble guanylate cyclase (sGC) stimulator, endothelin receptor antagonists (ERA), and prostacyclin
with mixed results.
Experimental models and human studies have
shown that nitric oxide-dependent pulmonary
vasodilation is impaired in heart failure and contributes to endothelial dysfunction.25 These observations led to the investigation of PD5i and sGC as
potential treatment options for PH-LHD.
Guazzi and colleagues studied sildenafil 50 mg
three times a day for up to 12 months in a
double-blind, randomized, placebo-controlled
trial. Forty-four patients with HFpEF with echocardiographic evidence of PH (estimated RVSP 
40 mm Hg) were enrolled, and sildenafil showed
improvement in mean PA pressures, PVR, and
RV function.26 On the other hand, the RELAX
study, which included patients with HFpEF with
ejection fraction (EF) > 50%, failed to show a significant effect of sildenafil 60 mg three times a
day in the primary endpoint of change in peak oxygen consumption at 24 weeks of therapy.27 Secondary endpoints of 6-minute walk distance and a
clinical rank score -composite of death, hospitalization and change in heart failure questionnairewere also negative. Of note, RELAX did not require
the presence of PH as part of the inclusion criteria.
Hoendermis and colleagues studied the use of sildenafil 60 mg three times a day for 12 weeks in 52
patients with PH-HFpEF in a single-center, randomized, double-blind, placebo-controlled trial.
There was no change in the primary endpoint of
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mean pulmonary artery pressure at 12 weeks.28
Interestingly, neither of these studies required an
elevated PVR as part of the inclusion criteria and
most patients had an IpcPH hemodynamic profile.
DILATE-1 evaluated the hemodynamic effect of
a single dose of riociguat in patients with PHHFpEF (EF > 50%, mean PA  25 mm Hg, and
PCWP 15 mm Hg). There was no change in the primary endpoint of mean PA pressure compared to
placebo.
However,
riociguat
significantly
increased stroke volume and decreased systolic
blood pressure and RV end-diastolic area without
changing PCWP, transpulmonary gradient, and
PVR. As a follow-up, the phase IIb DYNAMIC
study was designed to evaluate the efficacy,
safety, and kinetics of riociguat in PH-HFpEF
over 26 weeks with a primary endpoint of change
in cardiac output. The results are not yet available.
Pieske and colleagues29 evaluated vericiguat in
patients with EF  45% in the SOCRATES PRESERVED trial. The primary outcomes of this study
were changed from baseline to week 12 in NTproBNP and left atrial volume, which showed no
improvement.
In patients with heart failure, plasma levels of
endothelin-1 are elevated and associated with
increased pulmonary pressure and higher risk for
mortality.30,31 Based on this observation, ERA
have been evaluated as potential treatment options for heart failure.
The MELODY-1 study enrolled 63 patients with
CpcPH confirmed by RHC and an EF >30%. In
this phase II trial, patients were randomized to
macitentan 10 mg daily or matching placebo for
12 weeks stratified by EF (<50% vs  50%).
The median PVR was 5.8 WU, PCWP 20 mm
Hg, and mean PA pressure 47 mm Hg; and
25% had EF <50%. At 12 weeks, the macitentan
group showed no significant change in PVR,
mean right atrial pressure, PCWP, and cardiac index. Notably, macitentan-treated patients were
qualitatively more likely to experience fluid retention (10% treatment difference).32 Bosentan,
another ERA, was also previously evaluated in patients with HFrEF in the REACH-1 and ENABLE
studies. Both of these trials were neutral for their
primary outcome and were associated with worsening heart failure early in the treatment
course.33,34
Levosimendan, an intravenous calcium sensitizer and inodilator, was evaluated in patients
with PH-HFpEF, with mean PA  35 mm Hg,
PCWP  20 mm Hg and EF  40%.35 Six weeks
of once-weekly infusions did not reduce the primary endpoint of peak exercise PCWP, but patients were noted to have a decrease in resting

PCWP as well as improvement in 6-minute walk
distance compared to placebo.
Currently, the CADENCE study (clinicaltrials.gov) is evaluating the effect of sotatercept—a
first-in-class ligand trap for TGF-b superfamily
ligands-in patients with PH-HFpEF and CpcPH.
The rationale for performing this study comes
from the PULSAR trial, which studied sotatercept
in patients with PAH and showed a significant
decrease in the primary endpoint of PVR, as well
as improvements in prespecified secondary outcomes of 6-minute walk distance, NT-proBNP,
and World Health Organization functional class.36
As seen, pulmonary vasodilators have shown
mixed results in the treatment of PH-LHD with
most results showing negative results and even
signals of harm. Many of these trials studied pulmonary vasodilators in HFrEF. Of those who studied these medications in PH-HFpEF, the definition
of PH was not uniform and not always based on
invasive hemodynamics. Moreover, a distinction
between IpcPH and CpcPH was not mandatory
in most studies.
There has been significant interest in further understanding the cardiac and vascular changes
leading to PH-HFpEF to help guide potential future
therapies outside of traditional pulmonary vasodilators.7 Vascular remodeling, metabolic syndrome
oxidative stress, and fibrosis are all targets for
future therapies. The vascular changes that occur
in PH-HFpEF are different than what is seen in a
patient with idiopathic PAH as well as patients
with PH-HFrEF, and therefore respond differently
to currently available therapeutic options. As well
as arterial remodeling, there is significant venous
remodeling and luminal narrowing that is similar
to changes observed in pulmonary venoocclusive disease.37 The increased left atrial pressures and the associated back pressure leads
causes barotrauma to the lung capillary and small
arteries. These changes lead to a breakdown of
the endothelial layer and increased permeability,
resulting in gas exchange inefficiency, disrupted
fluid filtration and reabsorption, and increased
risk of pulmonary edema.38 Patients with PHHFpEF compared with PH-HFrEF have been found
to have increased stiffness in the pulmonary circulation and vascular changes when compared to
patients with the same pulmonary capillary wedge
pressure leading to reduced pulmonary artery
compliance (PAC 5 stroke volume/pulmonary artery pulse pressure).39 Along with elevated pulmonary vascular changes and the uncoupling, further
assessment of the RV shows diffuse fibrosis out of
proportion to the degree of pulmonary hypertension in patients with PH-HFpEF.40
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Table 3
Results of completed clinical trials PH-HFpEF
First Author/Study Study Drug/Dose

Population (n) Duration

Guazzi
et al,26 2011

Sildenafil
50 mg TID

HFpEF
n 5 44

Hoendermis
et al,28 2015
MELODY-1

Sildenafil
60 mg TID
Macitentan
10 mg daily

HFpEF
n 5 52
HF (EF> 30%)
75% HFpEF
n 5 48

32

Burkhoff
et al,35 2021

Levosimendan
HFpEF
Weekly infusion
n 5 37
(0.075–0.1 ug/kg/min
for 24 hr)

Primary Outcome Result

12 months PVR, RV
Improvement
performance,
CPET
12 weeks mPAP vs placebo No change
12 weeks

Safety and
tolerability

6 weeks

Peak exercise
PCWP

110% fluid
retention
in active
group
No change

Abbreviations: CPET, cardiopulmonary exercise testing; EF, ejection fraction; HF, heart failure; HFpEF, Heart failure with
preserved ejection fraction; mPAP: mean pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PVR,
pulmonary vascular resistance; RV: right ventricular.

The variability of cardiac and vascular changes
for each individual patient has made it more difficult to assess the efficacy of therapy. The importance of separating patients into specific
phenotypes (i.e. IphPH, CpcPH, exercise PH,
and so forth) has been an important step to further
understanding the pathophysiology of the cardiac
and vascular changes, defining prognosis, and
serving as a basis for clinical trial design.7
To date, there are currently no FDA-approved
therapies for PH-HFpEF. Diagnosis and management of the underlying comorbidities–sleep apnea,
hypoxia, arrhythmias, hypertension, coronary artery, obesity disease, and diabetes mellitus
others—remains a focus of treatment of patients
with PH-HFpEF.

SUMMARY
PH is frequently seen in patients with HFpEF and is
associated with significantly greater symptom
burden and increased mortality. The echocardiogram remains the initial screening test for PH in
HFpEF and can generate an initial impression of
the type of PH present and RV function. The
RHC is the test of choice to define PH-HFpEF,
and also importantly, understand the underlying
hemodynamic profile (IpcPH vs CpcPH). The use
of pulmonary vasodilators in PH-HFpEF has been
evaluated in multiple clinical trials with mixed results. There are currently no FDA-approved therapies for PH-HFpEF . There is a significant interest
in finding an effective therapeutic option for this
population and clinical trials are currently

underway using novel mechanistic approaches in
well-defined phenotypes. Improving the understanding of the different phenotypes and mechanisms of injury in each subset of patients with
PH-HFpEF will be a critical step to improving the
treatment in the future (Table 3).

CLINICS CARE POINT

 There are currently no FDA approved medical
therapy for PH associated with HFpEF (PHHFpEF).
 Differentiating between pulmonary arterial
hypertension (PAH) and PH-HFpEF can be
difficult and requires a high degree of suspicion. Referral to a tertiary center may be
needed.

DISCLOSURE
The authors have nothing to disclose.

REFERENCES
1. Gerber Y, Weston SA, Redfield MM, et al.
A contemporary appraisal of the heart failure
epidemic in Olmsted County, Minnesota, 2000 to
2010. JAMA Intern Med 2015;175(6):996–1004.
2. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 14, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Pulmonary hyeprtension in HFpEF

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

classification of pulmonary hypertension. Eur Respir
J 2019;53(1):1801913.
Strange G, Playford D, Stewart S, et al. Pulmonary
hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart 2012;98(24):
1805–11.
Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013;62(25 Suppl):D100–8.
Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary
hypertension in heart failure with preserved ejection
fraction: a community-based study. J Am Coll Cardiol 2009;53(13):1119–26.
Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019;53(1):1801889.
Vachiery JL, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019;53(1):1801897.
Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019;
53(1):1–10.
Waxman A, Restrepo-Jaramillo R, Thenappan T,
et al. Inhaled treprostinil in pulmonary hypertension
due to interstitial lung disease. N Engl J Med 2021;
384(4):325–34.
Kovacs G, Berghold A, Scheidl S, et al. Pulmonary
arterial pressure during rest and exercise in healthy
subjects: a systematic review. Eur Respir J 2009;
34(4):888–94.
Caravita S, Dewachter C, Soranna D, et al. Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis.
Eur Respir J 2018;51(4):1702427.
Vanderpool RR, Saul M, Nouraie M, et al. Association between hemodynamic markers of pulmonary
hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 2018;3(4):
298–306.
Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/
ERS guidelines for the diagnosis and treatment of
pulmonary hypertension: the joint task force for the
diagnosis and treatment of pulmonary hypertension
of the European society of cardiology (ESC) and the
European respiratory society (ERS): endorsed by:
association for European paediatric and congenital
cardiology (AEPC), international society for heart
and lung transplantation (ISHLT). Eur Respir J
2015;46(4):903–75.
Shah AM, Claggett B, Sweitzer NK, et al. Cardiac
structure and function and prognosis in heart failure
with preserved ejection fraction: findings from the
echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail
2014;7(5):740–51.

15. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S–12S.
16. Lam CS, Borlaug BA, Kane GC, et al. Age-associated increases in pulmonary artery systolic pressure
in the general population. Circulation 2009;119(20):
2663–70.
17. Kjaergaard J, Akkan D, Iversen KK, et al. Prognostic
importance of pulmonary hypertension in patients
with heart failure. Am J Cardiol 2007;99(8):1146–50.
18. Mohammed SF, Hussain I, AbouEzzeddine OF, et al.
Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
Circulation 2014;130(25):2310–20.
19. Melenovsky V, Hwang SJ, Lin G, et al. Right heart
dysfunction in heart failure with preserved ejection
fraction. Eur Heart J 2014;35(48):3452–62.
20. McLaughlin VV, Shah SJ, Souza R, et al. Management of pulmonary arterial hypertension. J Am Coll
Cardiol 2015;65(18):1976–97.
21. Farber HW, Foreman AJ, Miller DP, et al. REVEAL
Registry: correlation of right heart catheterization
and echocardiography in patients with pulmonary
arterial hypertension. Congest Heart Fail 2011;
17(2):56–64.
22. Raza F, Dillane C, Mirza A, et al. Differences in right
ventricular morphology, not function, indicate the nature of increased afterload in pulmonary hypertensive subjects with normal left ventricular function.
Echocardiography 2017;34(11):1584–92.
23. Arkles JS, Opotowsky AR, Ojeda J, et al. Shape of
the right ventricular Doppler envelope predicts hemodynamics and right heart function in pulmonary
hypertension. Am J Respir Crit Care Med 2011;
183(2):268–76.
24. Opotowsky AR, Ojeda J, Rogers F, et al. A simple
echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc
Imaging 2012;5(6):765–75.
25. Moraes DL, Colucci WS, Givertz MM. Secondary
pulmonary hypertension in chronic heart failure:
the role of the endothelium in pathophysiology and
management. Circulation 2000;102(14):1718–23.
26. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection
fraction: a target of phosphodiesterase-5 inhibition
in a 1-year study. Circulation 2011;124(2):164–74.
27. Redfield MM, Chen HH, Borlaug BA, et al. Effect of
phosphodiesterase-5 inhibition on exercise capacity
and clinical status in heart failure with preserved
ejection fraction: a randomized clinical trial. JAMA
2013;309(12):1268–77.
28. Hoendermis ES, Liu LC, Hummel YM, et al. Effects of
sildenafil on invasive haemodynamics and exercise
capacity in heart failure patients with preserved
ejection fraction and pulmonary hypertension: a

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 14, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

539

Moles & Grafton

540

29.

30.

31.

32.

33.

34.

randomized controlled trial. Eur Heart J 2015;36(38):
2565–73.
Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in
patients with worsening chronic heart failure and
preserved ejection fraction: results of the SOluble
guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 2017;38(15):1119–27.
Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart
failure. Circulation 1992;85(2):504–9.
Pousset F, Isnard R, Lechat P, et al. Prognostic value
of plasma endothelin-1 in patients with chronic heart
failure. Eur Heart J 1997;18(2):254–8.
Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan
in pulmonary hypertension due to left ventricular
dysfunction. Eur Respir J 2018;51(2).
Kalra PR, Moon JC, Coats AJ. Do results of the
ENABLE (Endothelin Antagonist Bosentan for
Lowering Cardiac Events in Heart Failure) study
spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85(2–3):
195–7.
Packer M, McMurray J, Massie BM, et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure:
results of a pilot study. J Card Fail 2005;11(1):12–20.

35. Burkhoff D, Borlaug BA, Shah SJ, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized
placebo-controlled HELP trial. JACC Heart Fail
2021;9(5):360–70.
36. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 2021;384(13):1204–15.
37. Fayyaz AU, Edwards WD, Maleszewski JJ, et al.
Global pulmonary vascular remodeling in pulmonary
hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation
2018;137(17):1796–810.
38. Nguyen QT, Nsaibia MJ, Sirois MG, et al. PBI-4050
reduces pulmonary hypertension, lung fibrosis,
and right ventricular dysfunction in heart failure. Cardiovasc Res 2020;116(1):171–82.
39. Adir Y, Guazzi M, Offer A, et al. Pulmonary hemodynamics in heart failure patients with reduced or preserved
ejection
fraction
and
pulmonary
hypertension: similarities and disparities. Am Heart
J 2017;192:120–7.
40. Patel RB, Li E, Benefield BC, et al. Diffuse right ventricular fibrosis in heart failure with preserved ejection fraction and pulmonary hypertension. ESC
Heart Fail 2020;7(1):253–63.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on December 14, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

